文献速递肝病消化道肿瘤与早癌

十一次易位-2失活抑制产生IL-10的调节性B细胞以增强肝细胞癌抗肿瘤免疫

Ten-eleven translocation-2 inactivation restrains IL-10-producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2023-02-17

本文研究十一次易位-2(TET2)在肝细胞癌(HCC)中调控产生IL-10的调节性B细胞(IL-10+ B细胞)生成的作用及临床前景。HCC微环境氧化应激触发的B细胞TET2活化促进IL-10表达,而过继转移Tet2缺陷B细胞抑制HCC进展;芳香烃受体是TET2羟化Il10所必需。B细胞中高水平的IL-10、TET2和5hmc提示HCC患者预后不良,B细胞中TET2抑制可增强抗肿瘤免疫并改善抗PD-1治疗。

要点

  • HCC微环境氧化应激触发B细胞TET2活化,促进IL-10表达。
  • 过继转移Tet2缺陷B细胞可抑制HCC进展。
  • B细胞中TET2抑制增强抗肿瘤免疫,改善HCC抗PD-1治疗。

核心结论

  • 研究提出靶向TET2依赖的表观遗传干预以抑制HCC进展中IL-10+ B细胞的生成。
  • 研究将抑制TET2活性确定为HCC免疫检查点抑制剂的有前景的联合治疗。

研究设计与样本

  • 研究探讨TET2在HCC中IL-10+ B细胞生成中的作用及其临床应用前景。
  • 采用过继转移Tet2缺陷B细胞的方法观察对HCC进展的影响。
  • 利用B细胞中5hmc测定TET2活性以评估抗PD-1治疗疗效。

主要发现

  • HCC微环境氧化应激触发的B细胞TET2活化促进IL-10表达。
  • 过继转移Tet2缺陷B细胞抑制HCC进展。
  • 芳香烃受体是TET2羟化Il10所必需。
  • B细胞中高水平的IL-10、TET2和5hmc提示HCC患者预后不良。
  • B细胞中TET2抑制促进抗肿瘤免疫,改善HCC抗PD-1治疗。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: IL-10-producing regulatory B cells (IL-10 + B cells), a dominant regulatory B cell (Breg) subset, foster tumor progression. However, the mechanisms underlying their generation in HCC are poorly understood. Ten-eleven translocation-2 (TET2), a predominant epigenetic regulatory enzyme in B cells, regulates gene expression by catalyzing demethylation of 5-methylcytosine into 5-hydroxymethyl cytosine (5hmC). In this study, we investigated the role of TET2 in IL-10 + B cell generation in HCC and its prospects for clinical application. APPROACH AND RESULTS: TET2 activation in B cells triggered by oxidative stress from the HCC microenvironment promoted IL-10 expression, whereas adoptive transfer of Tet2 -deficient B cells suppressed HCC progression. The aryl hydrocarbon receptor is required for TET2 to hydroxylate Il10 . In addition, high levels of IL-10, TET2, and 5hmc in B cells indicate poor prognosis in patients with HCC. Moreover, we determined TET2 activity using 5hmc in B cells to evaluate the efficacy of anti-programmed death 1 (anti-PD-1) therapy. Notably, TET2 inhibition in B cells facilitates antitumor immunity to improve anti-PD-1 therapy for HCC. CONCLUSIONS: Our findings propose a TET2-dependent epigenetic intervention targeting IL-10 + B cell generation during HCC progression and identify the inhibition of TET2 activity as a promising combination therapy with immune checkpoint inhibitors for HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lu Z, Liu R, Wang Y, et al. Ten-eleven translocation-2 inactivation restrains IL-10-producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma. Hepatology. 2023. PMID: 35243663. doi:10.1002/hep.32442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。